Company to introduce significant product upgrades that enable treating multiple tumors in a single treatment plan to improve patient experience.
RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from multiple clinical programs will present pioneering scientific evidence in 37 oral and poster presentations confirming the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX® biology-guided radiotherapy (BgRT) at the 2024 American Association of Physicists in Medicine (AAPM) Annual Meeting in Los Angeles, July 21-25.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718915301/en/
Researchers from multiple clinical programs will present scientific evidence in 37 oral and poster presentations at the 2024 AAPM annual meeting, confirming the efficacy and feasibility of the RefleXion® X1 machine with SCINTIX® biology-guided radiotherapy. (Photo: Business Wire)
“Since last year’s AAPM, we have begun delivering SCINTIX therapy in the clinic, which required a significant effort to characterize and establish standards for this first-in-world radiotherapy approach. This year, we have 37 presentations that collectively reflect this collaborative effort between physicists, clinicians and researchers,” said Sean Shirvani, M.D., chief medical officer of RefleXion. “The rigor of our research, the scientific collaboration, and the potential impact on patient care are truly inspiring.”
The following four oral presentations and programs highlight new research showcasing the potential of SCINTIX therapy to optimize multi-target treatment planning with high dosimetric accuracy, the nuances of clinical workflows, the accuracy of multi-target SCINTIX therapy, and an introduction to BIGSTAR (Biological Image Guidance for Spatial-Temporally Adaptive Radiotherapy), an innovative approach that aims to enhance cancer patient management and treatment outcomes by focusing on intra-fraction immune response to direct adaptive radiotherapy based on tumor biology. Detailed information on all 37 presentations may be found here.
Oral Presentations and Invited Programs:
Oral: Initial Dosimetric Performance of Multi-Target, Multi-Treatment Area Image-Guided Radiotherapy in a Single Session, Mason Hazlett, M.S.
Sunday, July 21, 1:42 pm in Room 152
Invited Program: PET Guided Radiation Therapy 101, Dae Yup Han, Ph.D.
Tuesday, July 23, 8:06 am in Room 502A
Invited Program: Introduction and Overview of Current Technology for Biology-guided RT, Dae Yup Han, Ph.D.
Thursday, July 25, 8:30 am, Room 502A
Oral: Pulsar – a Biology-guided Radiotherapy Strategy That Optimizes Immuno-Radiotherapy Based on Intra-Fraction Immune Response, Robert Timmerman, M.D.
Thursday, July 25, 8:44 am, Room 502A
RefleXion is also hosting an industry lunch symposium during the AAPM annual meeting at 12:30 PM CDT on July 22. Physicists Murat Surucu, Ph.D., Arnold Pompos, Ph.D., Tyler Watkins, Ph.D., and David Carlson, Ph.D. will share their latest clinical experience with SCINTIX biology-guided radiotherapy, highlight early clinical cases and share Quality Assurance (QA) procedures and practices.
The company will also hold interactive SCINTIX technology demonstrations in its booth (#1407) focused on its recent product release that includes the ability to treat multiple targets, both SCINTIX therapy and SBRT targets, in a single treatment plan, and the availability of live PET data during treatment delivery. The rollout of these features, designed to improve the patient experience and physician confidence, is currently underway at all RefleXion installed base sites.
About RefleXion Medical
RefleXion is a privately held theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided radiotherapy for solid tumors located anywhere in the body. For more information, please visit www.reflexion.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718915301/en/
“The rigor of our research, the scientific collaboration, and the potential impact on patient care are truly inspiring.” Sean Shirvani, M.D., chief medical officer of RefleXion
Contacts
Amy Cook
acook@reflexion.com
+1 925-222-5094
